FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2232172076> ?p ?o ?g. }

• W2232172076 endingPage "18509" @default.
• W2232172076 startingPage "18509" @default.
• W2232172076 abstract "18509 Background: To evaluate the efficacy and toxicity of concurrent/consolidation chemoradiotherapy versus sequential chemoradiotherapy in unresectable stage III non-small cell lung cancer (NSCLC). Methods: Thirty-two patients with stage III unresectable NSCLC were randomly assigned to one of the two treatment arms. In the sequential arm, patients received induction chemotherapy with docetaxel (75 mg/m2) repeated every 3 weeks for 3 cycles, followed by thoracic radiotherapy at a dose of 61Gy in 33 fractions over 6.5 weeks. In the concurrent/consolidation arm, the same radiotherapy was started on day 2 with two concurrent cycles of (PE): cisplatin 50 mg/m2 on days 1, 8, 29, and 36; etoposide 50 mg/m2 on days 1 through 5 and 29 through 33. Then these patients received consolidation therapy with docetaxel started 4–6 weeks after concurrent chemoradiotherapy, repeated every 3 weeks for 3 cycles at a dose of 75 mg/m2. Results: The overall response rate was higher in concurrent/ consolidation arm (62.5%) than in sequential arm (43.7%), (P=0.031). The median survival was 19 months in concurrent/consolidation arm and 13.6 months in the sequential arm, (P=0.001). The 2- year survival rate was better in concurrent/consolidation arm (43.7%) than in the sequential arm (25%), (P=0.032). Median progression- free survival was longer in concurrent/consolidation arm (11.9 months) than in sequential arm (8 months), (P=0.071). The major and most frequent toxicity was neutropenia, which was 43.7% in concurrent/consolidation arm versus 56.2% in sequential arm, (P=0.09). However, esophageal toxicity (≥ grade 3) was relatively higher in concurrent/consolidation arm 25% versus 12.5% in sequential arm, (P= 0.05). Brain metastases was the most common site of distant failure in both treatment arms. Locoregional failure was more frequent in sequential arm (37.5%) than in concurrent/ consolidation arm (18.7%), (P=0.039). Conclusions: Consolidation docetaxel after concurrent cisplatin/etoposide with radiotherapy in stage III NSCLC was feasible, tolerable and can be safely administered with relatively low incidence of radiation esophagitis. In addition, treatment outcomes compared favorably with the sequential chemoradiotherapy. No significant financial relationships to disclose." @default.
• W2232172076 created "2016-06-24" @default.
• W2232172076 creator A5053906226 @default.
• W2232172076 creator A5082589831 @default.
• W2232172076 creator A5086224676 @default.
• W2232172076 date "2008-05-20" @default.
• W2232172076 modified "2023-09-25" @default.
• W2232172076 title "Sequential chemoradiotherapy versus concurrent chemoradiotherapy plus consolidation chemotherapy in unresectable stage III non-small cell lung cancer" @default.
• W2232172076 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.18509" @default.
• W2232172076 hasPublicationYear "2008" @default.
• W2232172076 type Work @default.
• W2232172076 sameAs 2232172076 @default.
• W2232172076 citedByCount "0" @default.
• W2232172076 crossrefType "journal-article" @default.
• W2232172076 hasAuthorship W2232172076A5053906226 @default.
• W2232172076 hasAuthorship W2232172076A5082589831 @default.
• W2232172076 hasAuthorship W2232172076A5086224676 @default.
• W2232172076 hasConcept C126322002 @default.
• W2232172076 hasConcept C141071460 @default.
• W2232172076 hasConcept C2776256026 @default.
• W2232172076 hasConcept C2776694085 @default.
• W2232172076 hasConcept C2777063308 @default.
• W2232172076 hasConcept C2778119113 @default.
• W2232172076 hasConcept C2778239845 @default.
• W2232172076 hasConcept C2778424827 @default.
• W2232172076 hasConcept C2781190966 @default.
• W2232172076 hasConcept C509974204 @default.
• W2232172076 hasConcept C71924100 @default.
• W2232172076 hasConceptScore W2232172076C126322002 @default.
• W2232172076 hasConceptScore W2232172076C141071460 @default.
• W2232172076 hasConceptScore W2232172076C2776256026 @default.
• W2232172076 hasConceptScore W2232172076C2776694085 @default.
• W2232172076 hasConceptScore W2232172076C2777063308 @default.
• W2232172076 hasConceptScore W2232172076C2778119113 @default.
• W2232172076 hasConceptScore W2232172076C2778239845 @default.
• W2232172076 hasConceptScore W2232172076C2778424827 @default.
• W2232172076 hasConceptScore W2232172076C2781190966 @default.
• W2232172076 hasConceptScore W2232172076C509974204 @default.
• W2232172076 hasConceptScore W2232172076C71924100 @default.
• W2232172076 hasIssue "15_suppl" @default.
• W2232172076 hasLocation W22321720761 @default.
• W2232172076 hasOpenAccess W2232172076 @default.
• W2232172076 hasPrimaryLocation W22321720761 @default.
• W2232172076 hasRelatedWork W2003291927 @default.
• W2232172076 hasRelatedWork W2277416945 @default.
• W2232172076 hasRelatedWork W2356838307 @default.
• W2232172076 hasRelatedWork W2384018637 @default.
• W2232172076 hasRelatedWork W2412908548 @default.
• W2232172076 hasRelatedWork W2431341115 @default.
• W2232172076 hasRelatedWork W2511367473 @default.
• W2232172076 hasRelatedWork W2891028327 @default.
• W2232172076 hasRelatedWork W3028665314 @default.
• W2232172076 hasRelatedWork W3031689446 @default.
• W2232172076 hasVolume "26" @default.
• W2232172076 isParatext "false" @default.
• W2232172076 isRetracted "false" @default.
• W2232172076 magId "2232172076" @default.
• W2232172076 workType "article" @default.